NMTR - 9 Meters eyes FDA filing in H2 to start trial of obesity drug NM-136

2023-04-05 09:25:05 ET

• 9 Meters Biopharma ( NASDAQ: NMTR ) expects to file an application to the U.S. Food and Drug Administration (FDA) in H2 2023 for starting a trial of its obesity therapy NM-136.
• The company said it received a written response from the FDA on a request for a Type B pre-IND (Investigational New Drug) meeting on the pre-clinical development of NM-136 to treat obesity.
• Based on the response, 9 Meters plans to submit the IND to the FDA in H2 for a phase 1 trial based on the completion of the preclinical program.
• "Receipt of a written response provides us with the information needed to finalize our plans to support an IND for this promising product, the timing of which will be dependent upon our financial position going forward," said 9 Meters President and CEO John Temperato.
• NMTR +1.51% to $1.36 premarket April 5

For further details see: